Drug intelligence / Profile preview

Sidea B12

Development stage: Unknown
Lead developer: Naturprodukte Dr. Pandalis
Modality: Small Molecules
Administration: Oral

Overview

Sidea B12 is a plant-based dietary supplement developed and manufactured by the German company Dr. Pandalis. It is derived from the Virginia mallow (*Sida hermaphrodita*), which is utilized as a natural, vegan-friendly source of Vitamin B12 (cobalamin). Unlike most Vitamin B12 supplements which are produced via bacterial fermentation, Sidea B12 is marketed as a phytotherapeutic option for the prevention and management of Vitamin B12 deficiency, particularly in individuals following vegan or vegetarian diets. The product is typically administered as oral lozenges and is categorized as a nutraceutical or food supplement.

Brand names: Sidea B12
Other names: Sida hermaphrodita extract

Targets

MMUT (Methylmalonyl-coenzyme A mutase)MTR (Methionine synthase)

Beyond the preview

Go deeper on Sidea B12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sidea B12.

Explore the full profile